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Objective: A novel gestational diabetes mellitus (GDM)
screening programme which involved offering screening
at the patient’s general practitioner (GP) compared with
the traditional hospital setting was trialled. This study
investigates perspectives of involved stakeholders on the
provision of GDM screening at both settings.
Design: Thematic analysis of the perspectives of
stakeholders involved in the receiving and provision of
GDM screening in both the GP and hospital settings
drawn from focus groups and interviews.
Participants: 3 groups of participants are included in
this research—patient participants, GP screening
providers and hospital screening providers. All were
recruited from a larger sample who participated in a
randomised controlled screening trial. Purposeful
sampling was utilised to select participants with a wide
variety of perspectives on the provision of GDM screening.
Setting: Participants were recruited from a geographical
area covered by 3 hospitals in Ireland.
Results: 4 themes emerged from thematic analysis—
namely (1) travel distance, (2) best care provision, (3)
sense of ease created and (4) optimal screening.
Conclusions: The influence of travel distance from the
screening site is the most important factor influencing
willingness to attend for GDM screening among women
who live a considerable distance from the hospital setting.
For patients who live equidistance from both settings,
other factors are important; namely the waiting facilities
including parking, perceived expertise of screening
provider personnel, access to emergency treatment if
necessary, accuracy of tests and access to timely results
and treatment. Optimal screening for GDM should be
specialist led, incorporate expert advice of GDM screening,
treatment and management, should be provided locally,
offer adequate parking and comfort levels, provide
accurate tests, and timely access to results and treatment.
Such a service should result in improved rates of GDM
screening uptake.
Trial registration number: ISRCTN41202110.
INTRODUCTION
Gestational diabetes mellitus (GDM) is
defined as ‘any degree of glucose intolerance
with onset or first recognition during preg-
nancy’.1 The most recent prevalence estimate
for GDM in Ireland is 12.4%.2 GDM preva-
lence rates are increasing due to increasing
maternal age and BMI at pregnancy.3 4
Untreated GDM has consequences for both
maternal and neonatal health in the short
term, including macrosomia, increased risk
of caesarean section delivery and increased
neonatal unit admission rates.2 5–7 In add-
ition, a history of GDM is associated with an
increased long-term risk for the development
of prediabetes and type 2 diabetes mellitus
in the mother and her offspring.8–12
Screening allows for timely identification of
the condition and thus allows for initiation
of treatment in a timely and effective
manner, where necessary, to minimise or
avoid the previously outlined complications.
A study by Gayet-Ageron et al13 showed that
98% of women determined that GDM
screening was acceptable and 89% deemed it
essential. However, screening uptake rates in
Ireland are suboptimal with a most recent
estimate of 44% found by the Atlantic
Diabetes in Pregnancy (DIP) consortium,
Strengths and limitations of this study
▪ The inclusion of all of the key stakeholders
involved in screening for gestational diabetes
mellitus (GDM) as part of the randomised con-
trolled screening trial is deemed a strength of
this study.
▪ The inclusion of a wide variety of stakeholders’
perspectives allows the results to be broadly rep-
resentative of the general population, another
strength of the study.
▪ A limitation of the study is that the participants
of this study were recruited from a defined area
along the Irish Atlantic seaboard, potentially lim-
iting the extrapolation of results nationally and
internationally.
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when screening was applied universally to a regional
pregnant population.2 Thus, it is likely that, even in uni-
versal screening protocols, a significant proportion of
positive cases go undiagnosed. Previous research postu-
lated that distance to the screening site is a barrier to
screening uptake and that provision of screening in a
location closer to the woman’s home would result in
improved rates of uptake.14
The approach to screening and diagnosis of GDM
internationally is disorderly.15 The protocols for screen-
ing and diagnosis vary not only between countries, but
also within countries. In Europe, selective screening
based on the presence of specified risk factors is more
frequently implemented in comparison with the USA
and Canada, where universal screening is the predomin-
ant practice. A variety of screening tests are also utilised
worldwide including the 2 h 75 or 100 g oral glucose tol-
erance test (OGTT), random glucose test, 50 g glucose
challenge test and fasting glucose test. The diagnostic
criteria for GDM also varies greatly and includes the
2013 WHO criteria, the 1999 WHO criteria, European
Association for the Study of Diabetes (EASD) criteria,
Carpenter and Coustan criteria, and various national
standards. Less well researched is the variety of locations
in which GDM screening occurs. In Europe generally,
screening is typically hospital based, whereas the practice
of general practitioner (GP)/community screening
appears to be practiced on a greater level in countries
such as the USA, Canada and New Zealand.
Screening by GPs is successful for screening pro-
grammes in Ireland, for example, CervicalCheck—The
National Cervical Screening Programme. A randomised
controlled trial was undertaken in order to assess if
uptake rates for GDM screening improved when offered
at the patient’s GP setting compared with the hospital
setting.16 However, in this trial, uptake rates were super-
ior in the hospital setting compared with the GP setting,
despite the prior indications of Cullinan et al.14
This study sought to understand the perspectives
about screening in both the GP and hospital settings
from the viewpoints of patients screened in both loca-
tions and the GP and hospital providers of the screening
in order to provide context to the findings of the rando-
mised controlled screening trial. Understanding stake-
holders’ perspectives is key to identifying optimal
screening strategies and approaches which take stake-
holders preferences and perspectives into consideration
and thus are likely to maximise screening uptake. The
knowledge generated by this study will allow for develop-
ment of recommendations to transform the current
GDM screening programme to allow for sustained maxi-
mised rates of screening uptake.
METHODS
Three groups of participants are included in this
research—patient participants, GP screening providers
and hospital screening providers.
Patient participants were recruited from a larger sample
who participated in the randomised controlled screening
trial.16 Women were purposively sampled from this popula-
tion to include those who had received a 75 g OGTT
between 24 and 28 weeks gestation at either their GP, or at
the hospital where they were receiving antenatal care, and
women who tested positive and negative for GDM (in
accordance with International Association of the Diabetes
and Pregnancy Study Groups (IADPSG) criteria) at each
location.
GP screening provider participants were recruited
from a larger sample of GP providers who participated
in the randomised controlled screening trial.16 GP
screening providers were purposively sampled from this
population to include those who (1) participated fully in
the trial, (2) dropped out of the trial or (3) did not
agree to participate in the trial.
Hospital screening providers were recruited from the
three hospitals involved in the randomised controlled
screening trial.16 Hospital screening providers were pur-
posively sampled from this population to include nurses
involved in scheduling, management and delivery of hos-
pital screening services at all three hospital screening
sites.
Telephone interviews were conducted with patient and
GP screening provider participants, while in-person
focus groups were conducted with the hospital screening
provider participants in each of the three hospital sites
where screening was conducted. Telephone interviews
were utilised with the patient and GP screening provider
participants as these were considered populations who
are deemed hard to reach for face-to-face interviews.17
Telephone interviews are reported to be productive and
successful in qualitative research.18
Semistructured interview guides were developed and
utilised for each of the three participant groups. The
interview guides included open-ended questions, to
elicit as much information on the participants’ experi-
ences as possible. A conversational style of interviewing
was adopted to encourage a comfortable and fluent dia-
logue which was rich in detail, while using the interview
schedule as a reference to ensure that all key topics were
covered. The research questions aimed to elicit the parti-
cipants’ perspectives of screening in each location
including the benefits and barriers to screening at each
location.
The interviews and focus groups were conducted by
one of two of the authors (MT or AO’D), both postdoc-
toral researchers who had previous experience of con-
ducting focus groups and interviews in clinical
populations. The interviews and focus groups were
audio-taped with the permission of each participant,
using a digital recorder. Interviews were transcribed ver-
batim and analysed using theoretical thematic analysis
with a semantic approach as outlined by Braun and
Clarke.19 Thematic analysis is a particular type of qualita-
tive analysis which focuses on recognising, analysing and
reporting patterns (themes) within a qualitative data set.
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A semantic approach, focusing on the explicit meaning
of the data, was chosen. This approach extends beyond
a description of the themes to an interpretation of the
significance and implications of the themes identified.
Transcripts were reviewed independently by two of the
authors (MT and AO’D) who followed the phases out-
lined by Braun and Clarke.19 Phase 1 involved familiar-
isation with the data, reading and re-reading of the
transcripts and noting of initial ideas. Phase 2 involved
generating initial codes in a systematic fashion across the
entire data set. Phase 3 involved collating the codes into
potential themes. Phase 4 involved reviewing of the
themes and ensuring that they are relevant in relation to
both the coded extracts and the entire data set. Phase 5
involved refining the themes to ensure that they provide
a clear reflection of the overall story portrayed in the
data set. Both authors met regularly to identify common
themes and discuss areas of agreement and divergence.
This study was conducted in accordance with the
Declaration of Helsinki. An information letter was sent
to each participant and informed consent was provided
prior to interview or focus group participation.
RESULTS
This study includes 14 patient participants, 13 GP
screening providers and 11 hospital screening providers.
Thematic analysis revealed four themes which are dis-
cussed in more detail below. Three are related to the
benefits and barriers to screening at both assessed loca-
tions, while the fourth theme involves opinions on the
optimal screening strategies.
Theme 1: travel distance
There appeared to be differences in opinions about the
impact of travel distance on screening uptake depending
on how far from the hospital screening site the woman
was located. For women living in locations situated a
long distance from the hospital setting, the provision of
screening at their GP surgery which negated the require-
ment for an extensive journey was overwhelmingly
viewed as a particularly advantageous. The necessity for
extended fasting as part of the screening process rein-
forced the benefits of localised screening.
I do think the offering of it (GDM screening) through
the GP was a very good idea especially as I am an hour
away from my local hospital so I would have to go early
in the morning and spend 3 and a half hours in the hos-
pital. It’s a long day when you haven’t had anything to
eat and you’re sitting around waiting. Whereas because I
did it at my GP you are local to home so when you are
finished you are going home and you have something to
eat fairly quickly. (Patient screened at GP)
This view was also shared by both GP and hospital pro-
viders. GP providers make reference to the additional
stress that the long early morning journey causes.
I think it (screening at the GPs) is a lot easier than the
hospitals. I think it (hospital screening) is a lot more
hassle. Maybe if you’re living in the city it is fine, but for
someone living out here (80 kms from hospital), you’re
leaving here at half seven at the latest. (GP provider)
Noteworthy, hospital providers felt that currently their
attendance rates for GDM screening are impacted by
the distance the woman has to travel with those located
furthest from the hospital setting less likely to attend.
There is a role for them (GPs) in conducting OGTTs for
women who live a distance from the hospital, in particu-
lar for areas like Clifden (75 kms) and Ennis (65 km) as
these are locations where women are less likely to comply
with OGTT referral and don’t show. (Hospital provider)
However, those women who lived equidistance from
their GP and the hospital setting reported no preference
for either location or in some cases preferred the hos-
pital setting over the GP setting as a location to receive
their screening.
It really doesn’t bother me…it was the same thing for me
to go to the hospital as it was for my own GP. (Patient
screened in Hospital)
For the likes of me who are the same distance (from
both locations) I would say it is the hospital (that I would
prefer). (Patient screened at GP)
Theme 2: best care provision
Overall, the hospital setting was perceived to be superior
to the GP setting for GDM screening in terms of percep-
tion of best care provision. Thematic analysis revealed
four areas where differences are perceived between the
GP and hospital setting namely provider expertise, spe-
cialised equipment, timeliness of results and standardisa-
tion of screening.
Provider expertise
From the patient perspective, GP screening providers
were noted to show uncertainty about the procedures
associated with completing the test which negatively
influenced patients’ perceptions of GP expertise in pro-
viding screening.
She (the GP) wasn’t a hundred percent confident to be
honest. She kind of kept looking at the instructions; she
said ‘this is all new’. In the hospital it just seems to flow,
they were experts at it. (Patient screened at GP)
However, the GP screening providers did not report
that the provision of the test was challenging to them
indicating a discrepancy between the two participant
groups.
It’s pretty standard; my understanding is it is fairly rea-
sonable. (GP provider)
















pen: first published as 10.1136/bm





Patients appear to believe that the providers’ ability to
answer queries related to their pregnancy, GDM and
screening is an important component of the screening
process. Patients are aware that GPs are not specialists in
the area of GDM or indeed obstetrics or endocrinology,
and thus, many women believed that their GP did not
have sufficient knowledge of the condition of GDM or
its management to answer queries they had at the time
of screening.
I think that it would be better(to have screening) in the
hospital as you have a lot more access to people that
might answer any questions if you are concerned whereas
the GP might not be able to answer as many. (Patient
screened in Hospital)
Safety
Women appeared concerned that their health may be
compromised if an adverse event related to the GDM
screening procedure were to occur in the GP setting;
this was not a concern in the hospital setting as it is per-
ceived to have all of the specialised equipment and staff
to safely deal with such situations. Women perceive their
GP as a generalised rather than acute care provider, less
experienced in dealing with emergency situations. GP
providers are also conscious of their potential inability
to safely provide the screening.
I think the hospital might be better because GPs don’t
have as much equipment. When you take that liquid that
has sugar in it (Polycal) you might get dizzy so anything
can happen. So I think the hospital would be preferable.
(Patient screened in Hospital)
In the ideal world the service should be offered locally
but only if the facilities are available for it to be done
safely. (GP provider)
Timeliness of results
Women also expressed concerns about how quickly the
results of the screen would be relayed to them. Many
women felt that there would be a longer delay in having
results communicated to them if they were screened at
the GP, and thus it would take longer to instigate GDM
treatment where necessary. If screening occurred in the
hospital setting, it was felt that results would be reported
in a more expedited manner.
The problem with the GP would be that I would
presume it takes longer for the results. (Patient screened
in Hospital)
Accuracy
Despite the GP providers reporting their ability to
conduct the test accurately as part of this trial, GP provi-
ders reported concern regarding the ability to maintain
accurate standards in the long term, particularly in rela-
tion to the requirement for hourly blood draws. Many
GPs believed that maintaining accuracy of the timing of
blood draws would be difficult in the long term, consid-
ering the pressures on GP services in Ireland currently.
If you were saying that every antenatal lady were to have
it (GDM screening) and it were to be accurate I’d have
to say hand on heart that would be almost impossible to
do. (GP provider)
Hospital providers also had concerns over the accuracy
of GP-administered tests. Some hospital providers
reported that on a number of occasions, GP provider
standards during the trial were unsatisfactory.
They (GPs) are probably not used to doing glucose toler-
ance tests and for the odd one we discovered they might
only have done a fasting and a two hour maybe. The test
would be incomplete. (Hospital provider)
Theme 3: sense of ease created
Being in a space which promotes a sense of relaxation
and comfort appears to be an important consideration
for women in relation to the location that GDM screen-
ing is offered. In this cohort, women generally favoured
the GP surgery as a location which offers higher levels of
comfort during the screening appointment
The wait doesn’t feel as long (and is) more comfortable
at the GP. (Patient screened at GP)
It (hospital waiting area) is not a very easy area to relax
in. It’s not comfortable. I wouldn’t really think that that
area was a great area to wait in. (Patient screened in
Hospital)
Furthermore, the hospital screening providers were
cognisant of the limitations of the hospital setting in
terms of comfort
There are disadvantages with having an OGTT in the
hospital setting…overcrowded hot waiting room, some-
times with standing room only. (Hospital provider)
Furthermore, parking availability at the hospital
setting and associated cost were also cited as disadvan-
tages of the hospital settings which were mitigated in the
GP setting. Both the women and the providers expressed
that the lower stress related to parking at the GP setting
added to the sense of ease created by this location.
More convenient in terms of parking and everything.
(Patient screened in Hospital)
They don’t have the added problems of things like
parking fees. (GP provider)
Theme 4: optimal screening
The stakeholders involved in the GDM screening trial
voiced their opinions about the optimum screening
approach which they believed would lead to maximised
uptake rates. Thematic analysis revealed three themes:
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(1) population screened, (2) screening provider and (3)
screening location.
Population
Providers and patients differed in their views about to
whom GDM screening should be provided. Generally,
both GP and hospital providers believe that selective
screening based on GDM risk factors is the most appro-
priate screening strategy. Economic and resource factors
were cited as reasons for this decision.
It (universal screening) is a huge cost for probably some
very low risk women. I mean there are a lot of young
healthy women that you really don’t think are high risk
of diabetes and don’t turn out to have it (GDM). I think
defined criteria for at risk people (is preferable) rather
than screening everybody. (GP provider)
However, the patients are more likely to be advocates
for universal screening, indicating that they would like to
have the offer of having screening conducted in all cases.
I think that everybody should probably be screened in an
ideal world…I think it’s important that as many women as
possible would be screened. (Patient screened in Hospital)
Provider
All stakeholder groups agreed that the provider of GDM
screening should have specialised knowledge and
expertise in the area of GDM screening and manage-
ment. This relates to the ‘expertise’ theme previously
outlined where many women and hospital providers
believed that GP providers lacked the expertise to
provide information about GDM to their patients.
I actually feel it should be midwifery led. I’m not a
midwife and there was times they’d ask me questions and
I couldn’t answer them. (Hospital provider)
A benefit of the hospital is that there is a lot more access
to people that might answer questions, where the GP
might not be able to. (Patient screened in Hospital)
Location
The three stakeholder groups were in agreement that a
community location would be superior to the current
hospital setting of the trialled GP setting for the provi-
sion of GDM screening. It was felt that a specialised
service offered in the community setting such as in com-
munity health centres would incorporate all the benefits
of the GP setting (ie, shorter travel distance, parking,
comfort) and allow for the high standards of care asso-
ciated with the hospital setting be maintained.
The ideal situation is organising it in the community
health centres. (GP provider)
Definitely out in the community. (Hospital provider)
DISCUSSION
The aim of this study is to understand the perspectives
of stakeholders about GDM screening in GP and hos-
pital settings. Currently, neither location appears satisfac-
tory at ensuring maximised screening uptake rates.2 16
Based on factors identified by stakeholders, we aim to
make recommendations for a screening strategy for
GDM that will potentially lead to improved uptake rates
and therefore improved identification and management
of the condition.
Cullinan et al14 recommended that reducing the dis-
tance that women had to travel to receive their screen-
ing would improve uptake rates. Thus, it is unsurprising
that travel distance emerged as a theme in discussions
around the provision of screening in the two settings.
Thematic analysis indicates for women that live a consid-
erable distance from the hospital setting, travel distance
to the screening site is an important determinant of will-
ingness to attend for GDM screening. Shorter travel dis-
tance emerged as the principal benefit of the GP
screening setting over the hospital setting for these
women as this factor includes not only travel time and
cost but also the requirement for prolonged fasting asso-
ciated with longer travel distance. GP and hospital provi-
ders also recognise long travel distances as barriers to
screening in the hospital setting. For women who live
equidistant from both settings, factors other than
journey distance influence stakeholders’ perspectives of
the GP and hospital settings as screening locations.
One such factor was the perception of better care pro-
vision at the hospital setting. Women in this trial were
aware that GPs are not specialists in the area of GDM
and are less knowledgeable about management options
and less able to manage an adverse event safely should it
arise during the screening process. This perception of
better care provision in the hospital setting has previ-
ously been reported in other care situations, for
example, cancer survivors who cited the ‘non-expert in
cancer’ nature of GPs as a main reason for not using GP
services.20 The perception of GPs’ lack of expertise and
non-specialism in the area is likely to negatively influ-
ence patients’ confidence in GPs’ abilities to conduct
the test in the appropriate manner and resultantly, the
uptake of screening in this location. Furthermore,
women were of the opinion that their screen results
would take longer to process if the screen was con-
ducted in the GP setting, and therefore it would take
longer to initiate treatment where necessary. Perceived
delay to treatment associated with GP screening is likely
to impact womens’ engagement with the GP setting as a
location for the provision of GDM screening.
Furthermore, the reality is that with part-time GP
working, next day delivery of results and the communi-
cation of results via letter in many cases, means that the
GP setting may significantly have to make changes to
their delivery of care in order to successfully offer high-
quality GDM screening. Overall, the perception of
better care provision in the hospital setting represents a
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significant real barrier to successfully utilising the GP
setting to maximise uptake rates of GDM screening.
The GP setting was generally reported as the preferen-
tial location for GDM screening when considering the
waiting period during the screening appointment. This
is largely related to the comfort of the waiting area
which, in the hospital setting, was off-putting to some
women. This is particularly relevant as the waiting
period for this test is quite long (approximately 2.5 h).
Arneill and Devlin21 found that the comfort of the
waiting area was correlated with patients perception of
quality of care; thus, it is likely that women in this study
felt that the GP setting was advantageous in this regard.
Parking, in terms of finding sufficient spaces as well as
the financial cost, was also noted to be problematic in
the hospital setting but not evident generally in the GP
setting. Parking has frequently been mentioned as an
attribute of patient satisfaction with primary care over
secondary care22 and has commonly been included in
taxonomies of patient satisfaction with care.23 24 Thus,
the sense of ease which is created by the GP setting but
not by the hospital setting is an advantage of this loca-
tion which can positively impact on uptake rates for
GDM screening.
Despite attempting to impact the quantity of uptake,
it must be ensured that in whatever location screening
is provided, the quality of the test does not suffer. The
accuracy of the test in relation to receiving three separ-
ate blood tests and receiving each test at hourly inter-
vals was not deemed problematic by the patients in this
trial at either of the locations. However, both the GP
and hospital providers did feel that both of these
aspects caused difficulties in the GP setting and could
be problematic if there was a longer, larger roll out of
such a programme in the GP setting. If the GP setting
was to be utilised as a location for the provision of
GDM screening, it would be of vital importance that
GPs would be provided with additional training in
order to provide an efficient and effective service,
where high-quality accurate standards can be achieved
routinely. If, after additional training and reorientation
of service, high-quality and accurate standards cannot
be maintained at the GP setting, it would appear
unlikely that such a service could be recommended. It
would also be of vital importance that both GPs and
patients are confident that patient safety, particularly in
the case of an adverse event, can be maintained in the
GP setting. Similar to the necessity for accurate stan-
dards, if this aspect cannot be achieved in the GP
setting, after additional training for providers in this
clinical area, then it would be unlikely a GDM screen-
ing service in this location could be recommended. If a
community location, as was suggested by stakeholders,
is utilised, it is imperative that high standards, which
equal or surpass the current hospital standards, are
maintained irrespective of quantity, in order to appro-
priately treat GDM and avoid and minimise the related
consequences.
This study benefitted from the inclusion of all of the
key stakeholders involved in screening for GDM as part
of the randomised controlled screening trial.
Furthermore, our sampling strategy allowed inclusion of
a wide variety of perspectives to be included, including
women who received screening in both settings, with
both positive and negative results for GDM, GPs who
participated fully, in part and not at all in the rando-
mised controlled screening trial and nursing staff from
the three hospital sites of the randomised controlled
screening trial. This allows us to be confident that the
results reported are reflective of the key stakeholders. A
limitation of the study is that the participants of this
study were recruited from a defined regional area in
Ireland, and thus the results may not be suitable for
extrapolation to other areas nationally or internationally.
As previously outlined, the influence of travel distance
appears to be only relevant for women living a consider-
able distance from the hospital setting, something not
considered by the Cullinan et al14 study. Future research
should assess at what distance does this become a factor
and also consider the employment location of the
women and the distance from this employment location
to the screening site, which may be more important as a
factor for women who are employed outside the home.
Furthermore, in future GDM screening trials, taking
into account the perspectives of the stakeholders identi-
fied as part of this qualitative study is prudent. It is very
important to identify as many cases of GDM as possible
through screening, to minimise the impacts GDM has
on both maternal and neonatal health. Neither the hos-
pital2 nor the GP16 setting appears to provide the most
appropriate set of factors to maximise uptake rates to
allow for maximised identification of GDM cases. The
data provided by stakeholders in this study can positively
add to the findings of Cullinan et al14 and makes some
further recommendations as to the optimal screening
strategy for GDM screening which can maximise rates of
uptake and thus minimise or avoid the short-term and
long-term complications of the condition. It appears
that a service, which is specialist led, provided conveni-
ently local to the woman with good parking and comfort
levels, provides accurate tests as well as advice and
results in a manner which is deemed suitable to the
women, is most suited in this population and, if put in
place, should result in improved rates of screening
uptake.
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